Our achievements in research projects made in close collaboration with our partners are published in peer reviewed journals.
News &
European Commission grants orphan drug designation for EVOCellic
Important milestone: EVOMEDIS has received Orphan Drug Designation from the European Medicines Agency (EMA) for its novel cell therapy drug for the treatment of severe burns.
Read More
Kleine Zeitung
Die Behandlung von Verbrennungswunden ist das Spezialgebiet des Start-ups EVOMEDIS, das sich aufgrund der exzellenten Wundtherapie-Expertise in Graz am ZWT angesiedelt hat.
Read More
burns, 2020
A novel human ex-vivo burn model and the local cooling effect of a bacterial nanocellulose-based wound dressing
Read More
burns, 2019
Delivery of antiseptic solutions by a bacterial cellulose wound dressing: Uptake, release and antibacterial efficacy of octenidine and povidone-iodine
Read More
burns, 2019
Experience with Epifast® cryopreserved epidermal allograft in the treatment of superficial and deep second-degree burns: Retrospective study of 297 cases, 2010–2015
Read More
burns, 2019
Continuous pH monitoring in wounds using a composite indicator dressing — A feasibility study
Read More
burns, 2018
Uptake of PHMB in a bacterial nanocellulose-based wound dressing: A feasible clinical procedure
Read More
Join our open clinical network and profit from our devolpment expertise.